DRKS00011887已完成1 期
First in man study to evaluate the safety, tolerability and preliminary efficacy of the Fc-optimized FLT3 antibody FLYSYN for the treatment of acute myeloid leukemia patients with minimal residual disease - FLYSYN-101
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Age =18 years at the time of voluntarily signing an IEC-approved informed consent, there is no upper age limit
- •Diagnosis of AML according to WHO criteria
- •Confirmed FLT3 expression on leukemic cells
- •Known mutational status of FLT3 (FLT3-ITD, FLT3-TKD, FLT3 wild type)
- •Hematological CR (ANC count >1.000/µL, Thrombocytes > 100.000/µL), but MRD positivity after any therapy except allogeneic stem cell transplantation
- •Life expectancy of > 3 months
- •ECOG performance status = 2
- •Subject must be willing to receive transfusion of blood products
- •Be willing and able to comply with the study protocol for the duration of the study
- •Females of childbearing potential (FCBP) must undergo repetitive pregnancy testing (serum or urine) and results must be negative
- •Reliable contraception should be maintained throughout the study and for 6 months after study treatment
- •Unless practicing complete abstinence from heterosexual intercourse, sexually active FCBP must agree to use adequate contraceptive methods
- •Males (including those who have had a vasectomy) must use an effective barrier method of contraception throughout the study and for 6 months after study treatment if sexually active with a female of childbearing potential
- •All subjects must:
- •ounderstand that the investigational product could have a potential teratogenic risk.
- •obe counseled about pregnancy precautions and risks of fetal exposure.
- •obe able to comply with all study-related procedures, medication use, and evaluations.
排除标准
- •The presence of ANY of the following criteria will exclude a patient from study enrollment:
- •Patients proceeding to hematopoietic stem cell transplantation (suitable candidate and donor available, informed consent of patient)
- •Pregnant or breast feeding females
- •>5% blasts in bone marrow or extramedullary disease
- •Treatment with monoclonal antibody within 3 months before treatment with FLYSYN or known immunoglobulin intolerance
- •Known positivity for HIV, active HBV, HCV, or Hepatitis A infection
- •No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and/or other physicians involved in the treatment about study participation
- •No consent for biobanking
- •Presence of any medical/psychiatric condition or laboratory abnormalities which may limit full compliance with the study, increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
- •Prior history of malignancies, other than AML/myelodysplastic syndrome (MDS), unless the subject has (i) been free of the disease for = 2 years. (ii) Exceptions include the following: Basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, histological finding of prostate cancer of TNM stage 1.
- •Patients receiving any medication listed in the Appendix IV Prohibited Medications” (within 14 days prior to the first dose of study drug)
- •Uncontrolled infection, e.g. infection progressing under adequate antimicrobial/antifungal/antiviral treatment
- •Patients under ongoing treatment with another investigational medication or having been treated with an investigational medication within 14 days of screening
- •Current treatment with immunosuppressive agents
- •Systemic diseases (cardiovascular, renal, hepatic, etc.) that would prevent study treatment (e.g., creatinine >1.5x upper normal serum level; bilirubin, AST or AP >2.5x upper normal serum level; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)
研究者
相似试验
进行中（未招募）
1 期
First in human study to test the safety and preliminary efficacy of PPSGG, an antibody catcher in patients with anti-MAG neuropathyEUCTR2020-000067-23-FRPolyneuron Pharmaceuticals AG48
进行中（未招募）
1 期
First in human study to test the safety and preliminary efficacy of PPSGG, an antibody catcher in patients with anti-MAG neuropathyanti-MAG neuropathyMedDRA version: 21.1Level: LLTClassification code 10066137Term: Anti-MAG neuropathySystem Organ Class: 100000004852EUCTR2020-000067-23-GBPolyneuron Pharmaceuticals AG48
已完成
1 期
First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NOX-H94MedDRA - LLT 10002272 (Anämie / Anemia)D63Anaemia in chronic diseases classified elsewhereDRKS00003102OXXON Pharma AG64
进行中（未招募）
1 期
A study in healthy male volunteers to look at the safety and tolerability of the new test medicine GUB014295 and how it is taken up by the body when given as a single dose by injectioControlling obesityNutritional, Metabolic, EndocrineISRCTN85112396Gubra A/S48
已完成
1 期
A first-in-human study to evaluate the safety, tolerability and performance of uncoated and placebo-coated NanopatchesVaccination Delivery DeviceOther - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615000583549Vaxxas Pty Ltd18